Other Key Findings Metabolic improvements: Participants saw reductions in A1C (for those with prediabetes or diabetes), fasting glucose, and triglycerides Liver fat reduction: Retatrutide reduced liver fat by up to 50%, which is why Eli Lilly added a NASH-specific trial to the Phase 3 program Side effects: Mostly gastrointestinal (nausea, diarrhea, constipation), similar to other GLP-1 drugs but manageable with slow titration Discontinuation rate: About 10% of participants stopped due to side effects, comparable to tirzepatide and semaglutide Study limitation: The Phase 2 trial was only 48 weeks long
PMCID: PMC8074354
In contrast, we found very little evidence that the well-intentioned advice being given was unsafe, and it was not uncommon for recommendations for people to see a healthcare professional to be made
We verify benefits, confirm plan compatibility with Wegovy and other brands, and manage prior authorization from start to finish
10.1016/j.molliq.2024.125446 21 Bautista-SnchezD.Arriaga-CanonC.Pedroza-TorresA.De La Rosa-VelzquezI
The single dose of 70 mg/kg has been used in models of acute toxicity and is below the oral LD for rats (75100 mg/kg), causing significant yet non-lethal organ damage [23, 24]